

# Retinoic acid receptor agonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/R52B01101925EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: R52B01101925EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Retinoic Acid Receptor (RARs) Agonist - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinoic Acid Receptor (RARs) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Retinoic Acid Receptor (RARs) Agonist Understanding

#### Retinoic Acid Receptor (RARs) Agonist: Overview

Retinoic acid receptors (RARs) are nuclear hormone receptors of the NR1B class, which function as heterodimers with retinoid X receptors (RXRs). The retinoic acid receptors (RAR $\alpha$ , RAR $\beta$ , and RAR $\gamma$ ) are members of the nuclear receptor superfamily. Compounds which bind to and activate the RARs are termed retinoids and comprise both natural retinol (Vitamin A) metabolites and synthetic analogs. Upon binding of an agonist ligands to RAR results in dissociation of corepressor and recruitment of coactivator protein that, promotes transcription of the downstream target gene into mRNA and eventually protein. Several Retinoic Acid Receptors (RAR) agonists have therapeutic activity against a variety of cancer types. RAR agonists presenting novel structural and chemical features could therefore open new avenues for the discovery of

leads against breast, lung and prostate cancer or leukemia.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Retinoic Acid Receptor (RARs) Agonist R&D. The therapies under development are focused on novel approaches for Retinoic Acid Receptor (RARs) Agonist.

## Retinoic Acid Receptor (RARs) Agonist Emerging Drugs Chapters

This segment of the Retinoic Acid Receptor (RARs) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Retinoic Acid Receptor (RARs) Agonist Emerging Drugs

### Palovarotene: Clementia Pharmaceuticals (Ipsen)

Palovarotene is a RAR $\alpha$  agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene had received rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder.

### IRX 5183: Allergan (AbbVie)

IRX 5183 is a selective, orally available, third generation vitamin A derivative and first in class Retinoic Acid Receptor alpha (RAR $\alpha$ ) agonist. IRX 5183 is a drug that is designed to cause cancer cells to mature and then die. The drug is in Phase I/II clinical development for the treatment of cancer.

Further product details are provided in the report.....

## Retinoic Acid Receptor (RARs) Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Retinoic Acid Receptor (RARs) Agonist drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players working on Retinoic Acid Receptor (RARs) Agonist

There are approx. 15+ key companies which are developing the Retinoic Acid Receptor (RARs) Agonist. The companies which have their Retinoic Acid Receptor (RARs) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Clementia Pharmaceuticals (Ipsen).

### Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Retinoic Acid Receptor (RARs) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Retinoic Acid Receptor (RARs) Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Retinoic Acid Receptor (RARs) Agonist therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinoic Acid Receptor (RARs) Agonist drugs.

### Retinoic Acid Receptor (RARs) Agonist Report Insights

- Retinoic Acid Receptor (RARs) Agonist Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

### Retinoic Acid Receptor (RARs) Agonist Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

### Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing Retinoic Acid Receptor (RARs) Agonist

drugs?

How many Retinoic Acid Receptor (RARs) Agonist drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Retinoic Acid Receptor (RARs) Agonist?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinoic Acid Receptor (RARs) Agonist therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Retinoic Acid Receptor (RARs) Agonist and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Clementia Pharmaceuticals (Ipsen)

Nippon Shinyaku

Bausch Health Companies

Galderma

Avecho Biotechnology

Allergan (AbbVie)

Celgene

SciTech Development

## Polaryx Therapeutics

### Key Products

Palovarotene

Tamibarotene

IDP 126

CD-5789

Tretinoin topical

IRX 5183

Cintirorgon

Fenretinide intravenous

PLX-200

## Contents

- Introduction
- Executive Summary
- Retinoic Acid Receptor (RARs) Agonist: Overview
  - Structure
  - Mechanism of Action
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Retinoic Acid Receptor (RARs) Agonist – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
  - Retinoic Acid Receptor (RARs) Agonist companies' collaborations, Licensing, Acquisition -Deal Value Trends
- Retinoic Acid Receptor (RARs) Agonist Collaboration Deals
  - Company-Company Collaborations (Licensing / Partnering) Analysis
  - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
  - Comparative Analysis
- Palovarotene: Clementia Pharmaceuticals (Ipsen)
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- Tretinoin topical: Avecho Biotechnology
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I/II)
  - Comparative Analysis



IRX 5183: Allergan (AbbVie)

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Fenretinide intravenous: SciTech Development

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Retinoic Acid Receptor (RARs) Agonist Key Companies

Retinoic Acid Receptor (RARs) Agonist Key Products

Retinoic Acid Receptor (RARs) Agonist- Unmet Needs

Retinoic Acid Receptor (RARs) Agonist- Market Drivers and Barriers

Retinoic Acid Receptor (RARs) Agonist- Future Perspectives and Conclusion

Retinoic Acid Receptor (RARs) Agonist Analyst Views

Retinoic Acid Receptor (RARs) Agonist Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Retinoic Acid Receptor (RARs) Agonist

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Retinoic Acid Receptor (RARs) Agonist

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Retinoic acid receptor agonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/R52B01101925EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R52B01101925EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970